Tanaka Susumu, Matsunaga Hidenori, Kimura Masahiro, Tatsumi Ke ita, Hidaka Yoh, Takano Toru, Uema Takeshi, Takeda Masatoshi, Amino Nobuyuki
Department of Laboratory Medicine, Osaka University Graduate School of Medicine (D2), Yamada-oka 2-2, Osaka 565-0871, Suita, Japan.
J Neuroimmunol. 2003 Aug;141(1-2):155-64. doi: 10.1016/s0165-5728(03)00252-2.
There is a hypothesis that autoimmune abnormalities in neurotransmitter receptors might cause some psychiatric disorders. Using a sensitive radioligand assay, we detected serum autoantibodies to recombinant human muscarinic cholinergic receptor 1 (CHRM1, 34.4%), mu-opioid receptor (OPRM1, 13.1%), 5-hydroxytryptamine receptor 1A (HTR1A, 7.4%), and dopamine receptor D2 (DRD2, 4.9%) in 122 psychiatric patients. Positive antibodies to CHRM1 were found in 34.1%, 34.9%, 33.3%, and 9.1% of patients with schizophrenic disorders (n=44), mood disorders (n=63), other psychiatric disorders (n=15) and autoimmune diseases (n=33), respectively. All three patients with neuroleptic maliganant syndrome had high activities of autoantibodies to CHRM1, OPRM1, and/or HTR1A. Our data suggest that autoimmunity to neurotransmitter receptors might be associated with the induction of psychiatric symptoms and have some relation to neuroleptic malignant syndrome.
有一种假说认为，神经递质受体的自身免疫异常可能导致一些精神疾病。我们使用灵敏的放射性配体分析法，在122例精神疾病患者中检测到了针对重组人毒蕈碱胆碱能受体1（CHRM1，34.4%）、μ-阿片受体（OPRM1，13.1%）、5-羟色胺受体1A（HTR1A，7.4%）和多巴胺受体D2（DRD2，4.9%）的血清自身抗体。在精神分裂症患者（n = 44）、心境障碍患者（n = 63）、其他精神疾病患者（n = 15）和自身免疫性疾病患者（n = 33）中，CHRM1阳性抗体的检出率分别为34.1%、34.9%、33.3%和9.1%。所有3例抗精神病药恶性综合征患者的CHRM1、OPRM1和/或HTR1A自身抗体活性均较高。我们的数据表明，神经递质受体的自身免疫可能与精神症状的诱发有关，并且与抗精神病药恶性综合征有一定关系。
